Topics

Antiphospholipid antibodies and cardiovascular thrombosis

Chronic Inflammation Inflammation Initiation Complex Intercellular Communication & Diseases Cellular Stress

Antiphospholipid antibodies are persistent autoantibodies directed against phospholipids or phospholipid-binding proteins, principally lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I. Antiphospholipid syndrome (APS) is diagnosed when an appropriate antibody profile accompanies arterial, venous, or microvascular thrombosis or defined pregnancy morbidity. Cardiovascular manifestations include deep-vein thrombosis, pulmonary embolism, stroke, transient ischemic attack, myocardial infarction, valvular disease, renal microangiopathy, and chronic occlusive vasculopathy. Risk depends on antibody type, persistence, titer, combined positivity, and conventional thrombotic factors; lupus anticoagulant and high-risk profiles identify greater risk. Four decades after description, prevalence estimates and assay comparability remain imperfect Persistent laboratory positivity is essential because transient antibodies can occur outside APS, and classification criteria are not substitutes for individualized clinical diagnosis[1][2].

The antibodies are active drivers rather than diagnostic bystanders. They activate endothelial cells, monocytes, and platelets, increase tissue factor and thromboxane A2, and engage complement. Monocytes adopt pro-inflammatory and procoagulant states through NF-κB, mTOR, and NLRP3 signaling and release TNF, IL-6, and tissue factor. Neutrophils generate extracellular traps and adhere more strongly to endothelium, while activated platelets supply procoagulant surfaces and interact with leukocytes through P-selectin and CD40 ligand. Disturbed fibrinolysis and cellular proliferation contribute to both acute clotting and progressive intimal occlusion. This thromboinflammatory network explains why APS can affect vessels of every size and why anticoagulation may not correct all disease mechanisms Triple positivity, arterial history, conventional vascular risk, pregnancy context, and treatment adherence can alter recurrence risk even when patients share the same syndrome label[2][3][4].

Clinical management prioritizes recurrence prevention and risk-factor control. Long-term vitamin K antagonism is standard after unprovoked venous thrombosis, with intensity adapted to arterial events and bleeding risk; rivaroxaban is not recommended for triple-positive APS. High-risk asymptomatic carriers and selected lupus or obstetric populations may receive low-dose aspirin, while pregnancy management commonly combines aspirin and heparin. Recurrent thrombosis despite adequate therapy can prompt adherence review, risk-factor reassessment, increased anticoagulation intensity, low-dose aspirin, or low-molecular-weight heparin. Experimental directions target complement, extracellular traps, mTOR, NLRP3, platelet receptors, or endothelial activation, but they must complement rather than displace proven antithrombotic care without outcome evidence Complement and cellular pathways may explain anticoagulant-refractory disease, but adjunctive immune therapy should be tested against carefully documented therapeutic anticoagulation[1][3][5][6].

The main gaps are diagnostic heterogeneity and limited randomized evidence, especially after arterial events or standard-treatment failure. Testing is affected by interlaboratory variation and anticoagulant exposure, and transient antibody positivity should not be treated as APS. Future cohorts should harmonize assays, report complete antibody profiles, and distinguish macrovascular, microvascular, obstetric, valvular, and hematologic phenotypes. Trials should compare antithrombotic intensity and mechanism-directed adjuncts while measuring bleeding, recurrence, organ damage, and quality of life. Stroke studies need expert integration of clinical and laboratory findings because conventional vascular risks coexist. Precision treatment will require identifying whether coagulation, complement, neutrophils, platelets, or chronic vasculopathy dominates in an individual rather than applying one APS label to biologically different syndromes Standardized sample timing and assay interpretation are especially important during anticoagulant use, acute thrombosis, infection, or pregnancy, when test performance and baseline risk change[1][4][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10219 Rapamycin
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.

Source: Streptomyces hygroscopicus

mTOR   FKBP   Molecular Glues   Fungal   Autophagy   Endogenous Metabolite   Antibiotic   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
1470
HY-100523 ML385
ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma.
Keap1-Nrf2   Ferroptosis   Apoptosis   mTOR  
Breast Cancer   Colorectal Cancer   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma   Esophageal Cancer  
644
HY-10071 Y-27632
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
ROCK   Reactive Oxygen Species (ROS)   Akt   Ras   mTOR   Apoptosis   PAK   NADPH Oxidase   NF-κB   Autophagy  
Cancer   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis  
603
HY-12815A MCC950 sodium
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-12815 MCC950
MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-10358 MK-2206 dihydrochloride
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia.
Bcl-2 Family   Akt   mTOR   Apoptosis   GSK-3  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Large Cell Lung Carcinoma   Metastatic Breast Cancer   Lung Fibrosis  
494
HY-14648C Dexamethasone (Water Soluble)
Dexamethasone (Hexadecadrol) Water Soluble is a water-soluble form of Dexamethasone (HY-14648). Dexamethasone is a glucocorticoid receptor agonist, apoptosis inducer, and a common disease inducer in experimental animals. It can be used to construct models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has the potential to be used in COVID-19 research.(Sale size is the weight of dexamethasone)
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Coronavirus Infection   Depression   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   Hypertension  
402
HY-14648 Dexamethasone
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research.
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic   ADC Payloads  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Autoimmune Disease   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
402
HY-100381 Nigericin sodium salt
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.

Source: Streptomyces hygroscopicus

Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-127019 Nigericin
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-B0795 MHY1485
MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.
mTOR   Autophagy  
Breast Cancer   Pancreatic Cancer   Depression   Pain  
223
HY-B0579 Cyclosporin A
Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.

Source: the fungus Beauveria nivea.

Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
214
HY-17471A Metformin hydrochloride
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
AMPK   Autophagy   Mitophagy   Apoptosis   mTOR  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Parkinson's Disease   Chronic Pain   Obesity  
212
HY-B0627 Metformin
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
AMPK   Autophagy   Mitophagy   Apoptosis   mTOR  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Parkinson's Disease   Obesity   Lung Fibrosis  
212
HY-112879 Mito-TEMPO
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
Calcium Channel   Apoptosis   Mitochondrial Metabolism   NOD-like Receptor (NLR)   PINK1/Parkin   Autophagy  
Ischemic Stroke   Osteoporosis   Chronic Kidney Disease  
186
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-13003 Torin 1
Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.
mTOR   Autophagy  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Pain   Obesity   Lung Fibrosis  
140
HY-L001P Bioactive Compound Library Plus
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

General Bioactive Screening Libraries

131
HY-10218 Everolimus
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.
mTOR   FKBP   Autophagy   Apoptosis   Bacterial  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Pain   Digestive System Inflammation   Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Cytomegalovirus Infection   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
125
HY-101840A EIPA hydrochloride
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
TRP Channel   Autophagy   COX   Prostaglandin Receptor   Na+/H+ Exchanger (NHE)  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Pancreatic Cancer   Depression   Pain   Rheumatoid Arthritis  
112
HY-101840 EIPA
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
TRP Channel   Prostaglandin Receptor   Autophagy   COX   Na+/H+ Exchanger (NHE)  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Pancreatic Cancer   Depression   Pain   Rheumatoid Arthritis  
112
HY-L022P FDA-Approved Drug Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,663 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

97
HY-L021P Natural Product Library Plus
Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Natural sources may lead to basic research on potential bioactive components for commercial development as lead compounds in drug discovery. Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, many based on their use in traditional medicine. With the development of new molecular targets, there is an increasing demand for novel molecular diversity for screening. Natural products will play a crucial role in meeting this demand through the continued investigation of world’s bio-diversity, much of which remains unexplored. MCE provides a unique collection of 6,400 natural compounds that contains Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloid, Phenols, Acids and Aldehydes. Natural Product Library Plus, with more powerful screening capability, further complements Natural Product Library (HY-L021) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Natural Product Screening Libraries

92
HY-L003 Apoptosis Compound Library
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 3,650 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Signaling Pathway Targeting Libraries

90
HY-L035P Drug Repurposing Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing. MCE Drug Repurposing Compound Library plus contains 6,142 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

Drug Repurposing Series

89
HY-L026P Clinical Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 3,298 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

86
HY-L136 Coagulation and Anti-coagulation Compound Library
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,525 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Signaling Pathway Targeting Libraries

85
HY-L013 Neuronal Signaling Compound Library
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders. MCE designs a unique collection of 3,961 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Signaling Pathway Targeting Libraries

84
HY-L046 Anti-Cardiovascular Disease Compound Library
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 2,468 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Disease Focused Libraries

84
HY-L036P Covalent Screening Library Plus
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 6,121 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Structure Classified Libraries

83
HY-L087 Anti-Obesity Compound Library
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Disease Focused Libraries

83
HY-L193 PBCRBS Traditional Chinese Medicine Compound Library
Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields. MCE can supply 1,006 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.
83
HY-L207 Mass Spectrometry Human Endogenous Metabolite Library
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms. MCE can provide 661 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Metabolism Focused Libraries

83
HY-16569 Colchicine
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
Environmental Pollutants   Microtubule/Tubulin   Autophagy   Apoptosis   NOD-like Receptor (NLR)  
Digestive System Disease   Lung Cancer   Prostate Cancer   Viral Infection   Coronavirus Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Alzheimer's Disease   Lung Fibrosis  
77
HY-50876 Daporinad
Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression.
NAMPT   Autophagy   Apoptosis   mTOR   p38 MAPK   ERK  
Cancer  
67
HY-101952 Prostaglandin E2
Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
Organoid   Prostaglandin Receptor   Endogenous Metabolite  
Metabolic or Endocrine Disease   Cardiovascular Disease   SARS-CoV-2 Infection   Liver Failure  
62
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-12497 ANA-12
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.
Trk Receptor   NOD-like Receptor (NLR)   AIM2   Caspase  
Depression   Anxiety or Fear-Related Disease   Pain   CNS Infection   Behavioral Addiction  
41
HY-101502A SB290157 trifluoroacetate
SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
Complement System  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
36
HY-D0836 EDTA dipotassium dihydrate
EDTA dipotassium dihydrate is a metal ion chelator that forms stable and water-soluble chelates with a variety of metal ions. EDTA dipotassium is commonly used as a blood anticoagulant, which can effectively prevent blood coagulation and maintain the morphology and function of cells in blood samples. In the industrial field, EDTA dipotassium can be used to remove the adverse effects of metal ions and prevent oxidation and deterioration caused by metal ions.
DNA/RNA Synthesis  
33
HY-W127801 Ethylenediaminetetraacetic acid trisodium hydrate
Ethylenediaminetetraacetic acid (trisodium hydrate) is a class of organic compounds containing carboxylic acid functional groups. It is commonly used as a chelating agent in various industrial and medical applications, especially in the food and pharmaceutical industries. Ethylenediaminetetraacetic acid (trisodium hydrate) has strong metal ion binding properties and can be used to chelate trace metals that may affect product quality or stability. In addition, it is used as an anticoagulant in blood collection tubes and as a stabilizer in some cosmetic and personal care products.
Biochemical Assay Reagents  
29
HY-B0214 Prednisone
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus.
Glucocorticoid Receptor   Apoptosis  
Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Lung Fibrosis  
22
HY-B0131 Prostaglandin E1
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases.
Prostaglandin Receptor   Endogenous Metabolite  
Prostate Cancer   Myocardial Infarction   Heart Failure   Type 2 Diabetes   Obesity  
22
HY-108566 U-46619
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation.
Prostaglandin Receptor  
Blood or Cardio-cerebrovascular Disease  
16
HY-110136 PMX 205
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
Complement System  
Autoimmune Disease  
15
HY-50901 ONO-AE3-208
ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Prostaglandin Receptor  
Metabolic or Endocrine Disease   Prostate Cancer   Rheumatoid Arthritis  
14
HY-D0714 Tetrazolium Red
Tetrazolium Red (2,3,5-Triphenyltetrazolium chloride; TTC) is a not brain-penetrant, colorless, water-soluble dye that is reduced by mitochondrial enzymes to a deep red, water-insoluble compound (formazan) mainly in the mitochondria of living cells. Tetrazolium Red is used to observe the activity of dehydrogenase, and it turns colorless to red when exposed to hydrogen. Tetrazolium Red distinguishes between surviving and infarcted brain tissue after stroke. Tetrazolium Red has been used to stain heart tissue to measure the extent of acute lesions and also used to stain brain tissue to detect the size of the infarcted area. The absorption wavelength of Tetrazolium Red is 570 nm.
Biochemical Assay Reagents  
Blood or Cardio-cerebrovascular Disease  
14
HY-127105 Iptacopan
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
Complement System  
Metabolic or Endocrine Disease   Autoimmune Disease  
13
HY-B0647 Butylphthalide
Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.
p38 MAPK  
Inflammation or Immune System Disease   Lung Cancer   Neurodegenerative Disease   Pain   SARS-CoV-2 Infection  
12
HY-18966 PF-04418948
PF-04418948, a chemical probe, is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.
Prostaglandin Receptor  
Cancer   Metabolic or Endocrine Disease  
12
HY-17567 Heparin
Heparin is a highly sulfated glycosaminoglycan,that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Heparin significantly inhibits exosome-cell interactions.
Exosomes   Thrombin   Autophagy   Endogenous Metabolite   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease   Coronavirus Infection   Bacterial Infection  
11
HY-12956 Dinoprost
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.
Prostaglandin Receptor   Endogenous Metabolite   Autophagy   Apoptosis  
Metabolic or Endocrine Disease  
10
HY-15526 PSI-697
PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM.
P-selectin  
Cancer  
9
HY-B0195 Tranilast
Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
Angiotensin Receptor   Prostaglandin Receptor  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   SARS-CoV-2 Infection   Hypertension  
9
HY-106178 PMX-53
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
Complement System  
Cancer   Autoimmune Disease   Cardiovascular Disease  
9
HY-132179 Fucoidan
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.
Glycosidase  
Cancer   Metabolic or Endocrine Disease   Cardiovascular Disease  
9
HY-N0228 Scoparone
Scoparone is isolated from Artemisia capillaris Thunb., has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.
Others  
Cancer   Cardiovascular Disease  
8
HY-B1521 Aluminum Hydroxide
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines.
Environmental Pollutants   NOD-like Receptor (NLR)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
7
HY-P2136 COG1410
COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease.
Apolipoprotein   Apoptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
5
HY-17627 Avacopan
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Complement System  
Autoimmune Disease  
5
HY-116282 Dextran sulfate sodium salt (MW 5000)
Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR).
HIV   Complement System   Apoptosis  
Infection   Inflammation or Immune System Disease  
5
HY-P1918A Activated Protein C (390-404), human TFA
Activated Protein C (390-404), human TFA, a peptide of the activated protein C (a vitamin K-dependent serine protease), potently inhibits APC anticoagulant activity.
APC  
Blood or Cardio-cerebrovascular Disease  
4
HY-106139 Bimosiamose
Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.
P-selectin   L-Selectin   E-Selectin  
Inflammation or Immune System Disease   SARS-CoV-2 Infection  
4
HY-108764 Mipomersen sodium
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).
Apolipoprotein   HCV  
Lipid Metabolism  
4
HY-P9914 Eculizumab
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies.

Species: Human

Complement System  
CNS Infection   Visual System Disease   Blood Disease   SARS-CoV-2 Infection  
4
HY-101988 Prostaglandin D2
Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.
Prostaglandin Receptor   Endogenous Metabolite  
Allergic Asthma   Allergic Rhinitis   Urticaria  
4
HY-76082A L-Pyroglutamic acid sodium
L-Pyroglutamic acid sodium is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid sodium is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid sodium can be used as a biomarker for systemic lupus erythematosus (SLE).
Endogenous Metabolite  
Inflammation or Immune System Disease  
3
HY-P1036A Compstatin TFA
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
Complement System  
3
HY-122208 SGA360
SGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).
Apolipoprotein  
Inflammation or Immune System Disease  
3
HY-P1036 Compstatin
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
Complement System  
3
HY-76082 L-Pyroglutamic acid
L-Pyroglutamic acid is the levo-isomer of Pyroglutamic acid. L-Pyroglutamic acid is the biologically active enantiomer in humans. Pyroglutamic acid is an intermediate in glutathione metabolism. L-Pyroglutamic acid can be used as a biomarker for systemic lupus erythematosus (SLE).
Endogenous Metabolite  
Systemic Lupus Erythematosus  
3
HY-P3252AS Pegcetacoplan-13C3,15N TFA
Pegcetacoplan-13C3,15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
2
HY-103358 KF38789
KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM.
P-selectin  
Inflammation or Immune System Disease  
2
HY-P6306 CS-6253
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
Apolipoprotein   Amyloid-β  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
2
HY-P99644 ACT017
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.

Species: Human

Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
2
HY-P1050A COG 133 TFA
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM.
Apolipoprotein   nAChR  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
2
HY-N9481 Lipoteichoic acid
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin.

Source: Staphylococcus aureus

Complement System   Autophagy   mTOR   Akt   PI3K   ERK   Interleukin Related  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-P3252A Pegcetacoplan acetate
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Complement System  
Inflammation or Immune System Disease  
2
HY-P1428A RFRP-1(human) TFA
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
Neuropeptide Y Receptor  
Blood or Cardio-cerebrovascular Disease  
1
HY-P1505 C3a (70-77)
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-N0620 Mulberroside C
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease.
HCV   Enterovirus   PERK   Calcium Channel   P-selectin   HCN Channel   Ras   ERK   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Hepatitis C Virus Infection   Staphylococcus Aureus Infection  
1
HY-P99891 Rovelizumab
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.

Species: Human

Integrin  
Blood or Cardio-cerebrovascular Disease  
1
HY-N3307 (+)-Medioresinol
(+)-Medioresinol is a furofuran-type lignan with antifungal and antibacterial properties. (+)-Medioresinol synergizes with antibiotics to exert antimicrobial and antibiofilm effects. (+)-Medioresinol induces intracellular ROS accumulation and mitochondrial-mediated apoptosis in Candida albicans. (+)-Medioresinol inhibits LPS (HY-D1056)-stimulated IL-12p40 production. (+)-Medioresinol is a PGC-1α activator that protects against endothelial cell pyroptosis in ischemic stroke via the PPARα-GOT1 axis. (+)-Medioresinol can be used in research on fungal and bacterial infection, inflammation, and ischemic stroke.
Bacterial   Fungal   Reactive Oxygen Species (ROS)   Apoptosis   MMP   Interleukin Related   PI3K   Akt   mTOR   PPAR   PGC-1α   Pyroptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-P99263 Inclacumab
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P1505A C3a (70-77) TFA
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-P9987 Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-NP001 Cationic BSA Protein
Cationic BSA Protein (Cationic Bovine Serum Albumin) is a bovine serum albumin (BSA) modified with excess ethylenediamine, which has enhanced immunogenicity compared to native BSA. Positively charged primary amines block all negatively charged carboxyl groups, making Cationic BSA Protein a cationic protein. Cationic BSA Protein has remarkable neuroprotective effects on ischemic stroke when in combination with Tanshinone IIA (HY-N0135) .
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
1
HY-P99842A Dapirolizumab
Dapirolizumab is an antibody targeting CD40L (CD154). Dapirolizumab can be used in research related to systemic lupus erythematosus.

Species: Human

Transmembrane Glycoprotein  
Inflammation or Immune System Disease  
1
HY-103076 EZ-482
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas.
Apolipoprotein  
Alzheimer's Disease  
1
HY-W020658 L-α-Phosphatidylinositol
L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection.
HIV  
HIV-1 Infection  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P7533 Apolipoprotein H/APOH Protein, Human (HEK293, His)
Apolipoprotein H Protein, Human (HEK293, His) expresses in HEK293 with a His tag at the C-terminus. Apolipoprotein H (ApoH) is the main target of anti-phospholipid antibodies (aPLs) found in many patients with systemic lupus erythematosus and antiphospholipid syndrome (APS).

Species: Human; Source: HEK293

1
HY-P74375 C2/Complement C2 Protein, Human (HEK293, His)
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, His) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 2

1
HY-P81185 C5b-9 Antibody
C5b-9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to C5b-9.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

1
HY-184075S Nomelcitinib
Nomelcitinib is a TYK2 inhibitor that modulates the IL23 signaling pathway. Nomelcitinib is used for research on multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.
JAK   Interleukin Related  
Digestive System Disease   Digestive System Inflammation   Systemic Lupus Erythematosus   Multiple Sclerosis   Crohn's Disease   Psoriasis   Rheumatoid Arthritis  
/
HY-151547S MRS4719-d3
MRS4719-d3 is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC50 value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca2+]i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke.
Isotope-Labeled Compounds   P2X Receptor  
Neurological, Eye or Ear Disease  
/
HY-N7387R 3-​Oxocholic acid (Standard)
Butylphthalide (Standard) is the analytical standard of Butylphthalide. This product is intended for research and analytical applications. Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.
Reference Standards   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P992422 NG004
NG004 is a fully human monoclonal antibody targeting Nogo-A. NG004 reduces retinal Nogo-A levels, blocks the binding of the Nogo-A-receptor complex, and neutralizes the Nogo-A protein. NG004 can be used in studies related to diabetic retinopathy, stroke and acute spinal cord injury.

Species: Human

Transmembrane Glycoprotein  
Nervous System Injury   Retinopathy  
/
HY-P3649 D-Val-Leu-Lys-chloromethylketone
D-Val-Leu-Lys-chloromethylketone is a polypeptide containing three amino acids. D-Val-Leu-Lys-chloromethylketone can act as an anticoagulant.
Biochemical Assay Reagents  
Blood or Cardio-cerebrovascular Disease  
/
HY-P5528 2Abz-SLGRKIQIK(Dnp)-NH2
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)
Others  
/
HY-N3919 γ-Methoxyisoeugenol
γ-Methoxyisoeugenol (Compound 5) is an anticoagulant agent that remarkably prolongs the thrombin time with a good dose-effect relationship at concentrations from 6.25 to 100 mM, but shows no significant differences in prothrombin time.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-14914S1 Azilsartan-d4
Azilsartan-d4 is the deuterium labeled Azilsartan. Azilsartan is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
Apoptosis   Angiotensin Receptor   Reactive Oxygen Species (ROS)  
Cancer  
/
HY-P991956 ABB071
ABB071 is a humanized anti-CD180 monoclonal antibody. ABB071 can down-regulate the highly expressed TLR7 and IRF5 genes in systemic lupus erythematosus and induce the expression of PNPT1 and DNASE1L3 genes. ABB071 can inhibit the expression of genes related to the type I interferon pathway as well as interferon-stimulated genes (ISGs). ABB071 has anti-inflammatory activity and can reduce the levels of inflammatory cytokines. ABB071 can be used for research on systemic lupus erythematosus and psoriasis.
Transmembrane Glycoprotein   Toll-like Receptor (TLR)  
Systemic Lupus Erythematosus   Psoriasis  
/
HY-P4259 Hirullin P18
Hirullin P18 is a potent thrombin inhibitor. Hirullin P18 has an anticoagulant effect.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990376 Anti-Complement C5aR1 Antibody
Anti-Complement C5aR1 Antibody is a human recombinant antibody expressed in CHO cells, targeting C5AR/C5AR1 /C5R1. Anti-Complement C5aR1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-Complement C5aR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-17627S1 Avacopan-d4
Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
/
HY-P3235 E-76
E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases.
Factor VIIa  
/
HY-P1100 PM102
PM102 (HepArrest) is a heparin antagonist that can reverses the anticoagulant effect of heparin. PM102 potently binds heparin (Kd = 36 nM) in vitro.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-W705434 Dabigatran etexilate-d11
Dabigatran etexilate-d11 (BIBR 1048-d11) is the deuterium labeled Dabigatran etexilate (HY-10274). Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
Isotope-Labeled Compounds   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-B0214S2 Prednisone-d4
Prednisone-d4 is deuterated labeled Prednisone (HY-B0214). Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus.
Apoptosis   Glucocorticoid Receptor   Isotope-Labeled Compounds  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-NP0194B C1q Protein (rabbit)
C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-N0390G L-Glutamine (GMP)
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
mTOR   NF-κB   STAT   HIF/HIF Prolyl-Hydroxylase  
Inflammation or Immune System Disease   Ischemic Stroke   Osteoporosis   Osteoarthritis  
/
HY-N7955 23-O-Acetylcimigenol-3-O-α-L-arabinopyranside
23-O-Acetylcimigenol-3-O-α-L-arabinopyranside (Compound 1) is a triterpene glycoside found in the rhizomes of Cimicifuga heracleifolia.23-O-Acetylcimigenol-3-O-α-L-arabinopyranside does not inhibit the classical pathway of the complement system.
Others  
/
HY-N19128 Pulchinenoside J
Pulchinenoside J is a lupane-type triterpenoid saponin and a complement system inhibitor that acts via the classical pathway. Pulchinenoside J can be isolated from the roots of Pulsatilla chinensis.
Complement System  
/
HY-182607 SA buffer, 1×, pH 7.4
SA buffer, 1×, pH 7.4, is mainly composed of sodium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, etc. It is the most commonly used reagent for diluting serum and other samples in immunotoxicology experiments, and is used for complement determination experiments, etc.
Biochemical Assay Reagents  
/
HY-P11049 Stroke-homing peptide
Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue.
Others  
Neurological, Eye or Ear Disease  
/
HY-P11048 Thrombin-cleavable peptide
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke.
Thrombin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P4325 Hirudin (55-65) sulfated
Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.
Thrombin  
/
HY-151546S MRS4596-d4
MRS4596-d4 is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC50 value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke.
Isotope-Labeled Compounds   P2X Receptor  
Neurological, Eye or Ear Disease  
/
HY-N12265 Versicolactone B
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway.
Others  
Inflammation or Immune System Disease  
/
HY-P990377 Anti-Complement Factor B Antibody
Anti-Complement Factor B Antibody is a CHO-expressed human antibody that targets Complement Factor B. The Anti-Complement Factor B Antibody carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P991666 BMS-986090
BMS-986090 is a humanized monoclonal antibody antagonist targeting CD40. BMS-986090 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and focal segmental glomerulosclerosis (FSGS).

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-158485 M5 glycan (Man5)
M5 glycan (Man5) (Mannose-5 N-linked oligosaccharide; Oligomannose 5 glycan) is an N-linked glycan on glycoproteins on glycoproteins. M5 glycan (Man5) enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity.
Biochemical Assay Reagents  
/
HY-D3180 CDr20
CDr20 is a fluorescent chemical probe capable of crossing the blood-brain barrier. CDr20 undergoes glucuronidation catalyzed by the UDP-glucuronosyltransferase Ugt1a7c, which triggers a fluorescence turn-on response. CDr20 enables visualization of live microglial cells. CDr20 can be used for research on Alzheimer's disease, stroke, and autism.
Fluorescent Dye  
Cerebrovascular Disease   Alzheimer's Disease  
/
HY-A0145S Phenprocoumon-d5
Phenprocoumon-d5 is the deuterium labeled Phenprocoumon (HY-A0145). Phenprocoumon is a coumarin derivative that acts as a long acting oral anticoagulant and an antagonist of vitamin K.
Isotope-Labeled Compounds   VD/VDR  
Cancer  
/
HY-N0228R Scoparone (Standard)
Scoparone (Standard) is the analytical standard of Scoparone. This product is intended for research and analytical applications. Scoparone is isolated from Artemisia capillaris Thunb., has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.
Reference Standards   Others  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-18660S Ciraparantag-d8 (tetra(hydrochloride) diacetate)
Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
Isotope-Labeled Compounds   Factor Xa   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-W854549 Heparin pentasaccharide
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
Factor Xa  
Blood or Cardio-cerebrovascular Disease  
/
HY-N21519 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon
8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon is a phenalenone derivative found in the aerial parts of Helicteres angustifolia. 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon exhibits moderate anti-complement activity against the classical pathway and weak activity against the alternative pathway.
Complement System  
Inflammation or Immune System Disease  
/
HY-E70171 Heparan Sulfate 3-O-Sulfotransferase 1
Heparan Sulfate 3-O-Sulfotransferase 1 is a sulfotransferase. Heparan Sulfate 3-O-Sulfotransferase controls cellular production of the anticoagulant heparan sulfate related structure.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-N17623 Ainsliaeasin C
Ainsliaeasin C, a 7-hydroxycoumarin derivative, is an orally active anticoagulant agent that can be found in Ainsliaea fragrans. Ainsliaeasin C exerts anticoagulant activity both in vitro and in vivo. Ainsliaeasin C can be used for the research on thrombotic disorders.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-W049802 N-((Allyloxy)carbonyl)-N-methyl-L-alanine
N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-N13251 Verbena Extract
Verbena Extract is a verbena extract. Verbena Extract is a potential anti-ischemic stroke agent, and its mechanism may be related to IL17A-mediated neuroinflammation regulation..
Others  
Neurological, Eye or Ear Disease  
/
HY-P1949 Cyclic MKEY
Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice.
CXCR  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P991604 MLN2201
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research.

Species: Human

Integrin  
Inflammation or Immune System Disease  
/
HY-N0361S Dihydrocapsaicin-d3
Dihydrocapsaicin-d3 is the deuterium labeled Dihydrocapsaicin (HY-N0361). Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat.
Isotope-Labeled Compounds   Reactive Oxygen Species (ROS)   PI3K   Bcl-2 Family   Caspase   Apoptosis   TRP Channel   Akt  
/
HY-W750238 Scoparone-13C2,d6
Scoparone-13C2,d6 is the deuterium and 13C labeled Scoparone (HY-N0228). Scoparone is isolated from Artemisia capillaris Thunb., has anticoagulant, vasorelaxant antioxidant, anti-inflammatory activities.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11209 Knob A peptide GPRPFPAC
Knob A peptide GPRPFPAC is a fibrin knob peptide. PEGylated Knob A peptide GPRPFPAC has enhanced anticoagulant activity.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-182665 Sterile Sodium Citrate Anticoagulant (4%)
Sterile Sodium Citrate Anticoagulant (4%) is a ready-to-use solution that prevents blood clotting by chelating with calcium ions. It is mainly used in experiments such as coagulation tests and erythrocyte sedimentation rate (ESR) measurements.
Biochemical Assay Reagents  
/
HY-107966 Heparin calcium (MW 15000-19000)
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
Thrombin   Factor Xa   Autophagy   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-B0647R Butylphthalide (Standard)
Butylphthalide (Standard) is the analytical standard of Butylphthalide. This product is intended for research and analytical applications. Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.
Reference Standards   Others  
Neurological, Eye or Ear Disease  
/
HY-W015777R 4-Methoxybenzyl alcohol (Standard)
4-Methoxybenzyl alcohol (Standard) (P-Methoxy-benzyl alcoho (Standard); (4-Methoxyphenyl)methanol (Standard)) is the analytical standard of 4-Methoxybenzyl alcohol (HY-W015777). This product is intended for research and analytical applications. 4-Methoxybenzyl alcohol (P-Methoxy-benzyl alcoho; (4-Methoxyphenyl) methanol) is a naturally derived volatile aromatic compound. 4-Methoxybenzyl alcohol upregulates the phosphorylation level of PI3K/Akt pathway proteins, downregulates the expression of pro-inflammatory factors, increases the content of tight junction proteins occludin and claudin-5, and alleviates structural damage to the blood-brain barrier. 4-Methoxybenzyl alcohol improves the decrease in viability and NO level of cerebral microvascular endothelial cells induced by oxygen-glucose deprivation/reperfusion, and reduces the release of lactate dehydrogenase. 4-Methoxybenzyl alcohol serves as a substrate in the two-phase persulfate-mediated electro-oxidation system, where it is directionally oxidized to p-anisaldehyde. 4-Methoxybenzyl alcohol acts as a substrate for wild-type fungal aryl alcohol oxidase. 4-Methoxybenzyl alcohol can be used in studies related to ischemic stroke, as well as in research across various fields such as chemical synthesis, including the synthesis of fragrances and flavorings.
Reference Standards   Drug Intermediate   Interleukin Related   TNF Receptor   Claudin   Akt   NO Synthase  
/
HY-N0115R Gastrodin (Standard)
Gastrodin (Standard) is the analytical standard of Gastrodin. This product is intended for research and analytical applications. Gastrodin, a main constituent of a Chinese herbal medicine Tianma, has been known to display anti-inflammatory effects. Gastrodin, has long been used for treating dizziness, epilepsy, stroke and dementia.
Reference Standards   Others  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N12189 3β-(Acetyloxy)stigmast-5-en-7-one
3β-(Acetyloxy)stigmast-5-en-7-one has anti-complement activity.
Others  
/
HY-P991313 PD-360324
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research.

Species: Human

c-Fms  
Inflammation or Immune System Disease  
/
HY-107203S Propentofylline-d6
Propentofylline-d6 (HWA 285-d6) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders.
Isotope-Labeled Compounds   Phosphodiesterase (PDE)   Adenosine Receptor  
Colorectal Cancer   Alzheimer's Disease  
/
HY-B0214S1 Prednisone-d7
Prednisone-d7 (Dehydrocortisone-d7) is deuterium labeled Prednisone. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus.
Isotope-Labeled Compounds   Glucocorticoid Receptor   Apoptosis  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-W744643 Butylphthalide-d9
Butylphthalide-d9 (3-n-Butylphthalide-d9) is deuterium labeled Butylphthalide. Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.
Isotope-Labeled Compounds   Others  
Neurological, Eye or Ear Disease  
/
HY-P99606 Cirevetmab
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator.

Species: Canlupfam

TGF-beta/Smad  
Inflammation or Immune System Disease  
/
HY-P1398 Compstatin control peptide
Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
Complement System  
Inflammation or Immune System Disease  
/
HY-B0647S1 Butylphthalide-d3
Butylphthalide-d3 is the deuterium labeled Butylphthalide. Butylphthalide(3-n-Butylphthalide), an anti-cerebral-ischemia agent, is first isolated from the seeds of celery and showes efficacy in animal models of stroke.
Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-10163S Dabigatran-d4
Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
Isotope-Labeled Compounds   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P5117 TAT-CIRP
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice.
Toll-like Receptor (TLR)  
Neurological, Eye or Ear Disease  
/
HY-P991439 BIIB023
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-10274S Dabigatran etexilate-d13
Dabigatran etexilate-d13 is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
Isotope-Labeled Compounds   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P6084 RP-220
RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research.
NOD-like Receptor (NLR)   p38 MAPK   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P992102 Ascuprubart
Ascuprubart is an anti-human monoclonal antibody targeting Complement C5.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P4155 SSA antigenic peptide TFA
SSA antigenic peptide is an antigenic peptide of Sjögren's syndrome-related antigen A (SSA). SSA antigenic peptide can be used for the research of systemic lupus erythematosus.
Biochemical Assay Reagents  
Systemic Lupus Erythematosus  
/
HY-N2996 Ganodermanondiol
Ganodermanondiol is a melanogenesis inhibitor isolated from the Ganoderma lucidum.Ganodermanondiol exhibits potent cytoprotective effects on tert-butyl hydroperoxide-induced hepatotoxicity. Ganodermanondiol shows significant anti-HIV-1 protease activity with an IC50 of 90 μM. Ganodermanondiol exhibits a strong anticomplement activity against the classical pathway of the complement system with an IC50 of 41.7μM.
HIV Protease  
Infection  
/
HY-B0325S Phenindione-d5
Phenindione-d5 is deuterium labeled Phenindione, which is an anticoagulant which functions as a Vitamin K antagonist.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-N0329 Deltaline
Deltaline is a diterpenoid alkaloid and isolated from plants of the genus Delphinium delavayi Franch. Deltaline itself has analgesic properties, and plants of the genus Delphinium delavayi Franch have also been therapeutically used to treat rheumaticpain, paralysis due to stroke, rheumatoid arthritis.
Others  
Neurological, Eye or Ear Disease   Rheumatoid Arthritis  
/
HY-N7401 Entadamide-A-β-D-glucopyranoside
Entadamide-A-β-D-glucopyranoside is one of the major components in the seeds of Entada phaseoloides. Entadamide-A-β-D-glucopyranoside has anti-complement activitie.
Complement System  
Autoimmune Disease  
/
HY-182664 Alsever's Solution
Alsever's Solution is an isotonic balanced salt solution that protects red blood cells and is commonly used as an anticoagulant or blood preservative. Alsever's Solution is primarily composed of citric acid, sodium citrate, glucose, and sodium chloride, with a pH of 5.9-6.3. The solution is aseptically processed.
Biochemical Assay Reagents  
/
HY-P3709 TRAF6 peptide
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke.
p62   E1/E2/E3 Enzyme  
Neurological, Eye or Ear Disease  
/
HY-108739 Idarucizumab
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990378 Anti-Complement Factor P/Properdin Antibody
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P99816 Ralpancizumab
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.

Species: Human

PCSK9  
Metabolic or Endocrine Disease  
/
HY-NP0194C C1q Protein (rat)
C1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-P99767 Olendalizumab
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus.

Species: Human

Complement System  
Infection  
/
HY-P1949A Cyclic MKEY TFA
Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice.
CXCR  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N1179 Tanshinone IIB
Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis.
Apoptosis  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N7671 Euphorbetin
Euphorbetin exhibits anticoagulant activities.
Others  
Cancer   Cardiovascular Disease  
/
HY-P99298 Lampalizumab
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P11315 MG1 peptide
MG1 peptide is an M1 microglia-targeting peptide with blood-brain barrier permeability. MG1 peptide can be used in studies related to ischemic stroke and cerebral ischemia-reperfusion injury.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P99336 Enlimomab
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .

Species: Human

Integrin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-10163S1 Dabigatran-d3
Dabigatran-d3 is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10887 Pegevongitide
Pegevongitide (AV-001) is a Tie2 agonist. Pegevongitide resists the increased endothelial cell permeability induced by SARS-CoV-2 infection. Pegevongitide activates the angiogenin (angiogenin)/Tie2 signaling pathway. Pegevongitide reduces perivascular space dilation and upregulates perivascular Aquaporin-4 expression. Pegevongitide decreases the expression of TNF-α, PAI-1, CXCL9 and P-selectin, improves white matter integrity, enhances cognitive function and exerts neuroprotective effects. Pegevongitide improves white matter integrity in middle-aged rats with vascular dementia induced by multiple microinfarctions. Pegevongitide can be used in related research on diseases such as COVID-19 and vascular dementia.
Tie   ANGPTL   SARS-CoV   Aquaporin   TNF Receptor   PAI-1   CXCR   P-selectin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   SARS-CoV-2 Infection  
/
HY-10264S Edoxaban-d6
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment.
Factor Xa   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P2023 Hirugen
Hirugen is a derivative of hirudin, an anticoagulant protein found in leeches.
Drug Derivative  
/
HY-P10275 Tat-NTS peptide
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke.
Apoptosis  
Neurological, Eye or Ear Disease  
/
HY-P6442 Chemerin15
Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
Chemerin Receptor   Syk   ERK   Src   p38 MAPK   P-selectin  
Cerebrovascular Disease   Cardiovascular Disease   Ischemia-Reperfusion Injury  
/
HY-P99443 Aselizumab
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.

Species: Human

P-selectin  
Inflammation or Immune System Disease  
/
HY-P5883 TAT-M2NX
TAT-M2NX (tatM2NX) is a selective inhibitor targeting human TRPM2 channels and exerts inhibitory effects on ischemic stroke. TAT-M2NX reduces H2O2-induced calcium influx via TRPM2 channels. After traumatic brain injury in mice, TAT-M2NX preserves hippocampal long-term potentiation, improves memory function, and reduces infarct volume after middle cerebral artery occlusion, but it shows no effect on female mice. TAT-M2NX can be used in studies related to traumatic brain injury and ischemic stroke.
TRP Channel  
Ischemic Stroke  
/
HY-P2920 Protamine from salmon
Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro.
Biochemical Assay Reagents   Thrombin   Bacterial  
Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-P99358 Dezamizumab
Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-107966A Heparin calcium (MW 3600-5000)
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
Thrombin   Factor Xa   Autophagy   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N1464A Aristolone
Aristolone is a sesquiterpene that can be isolated from Aristolochia debilis, Rosmarinus officinalis and Ficus Auriculata. Aristolone in Ara Fruit can be used as a prediction of apoptosis in HeLa cells. Aristolone inhibits the C1 complement component. Aristolone produces cytotoxicity effects on cells. Aristolone has anticancer properties and can be studied in research for cervical cancer.
Complement System   Apoptosis  
Cancer   Digestive System Disease   Autoimmune Disease   Digestive System Inflammation  
/
HY-110281R Dehydroascorbic acid (Standard)
Dehydroascorbic acid (Standard) is the analytical standard of Dehydroascorbic acid. This product is intended for research and analytical applications. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke.
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-132828 Odatroltide
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
P-selectin  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99786 Pozelimab
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases.

Species: Human

Complement System  
Metabolic or Endocrine Disease  
/
HY-P99267 Rontalizumab
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-W015777 4-Methoxybenzyl alcohol
4-Methoxybenzyl alcohol (P-Methoxy-benzyl alcoho; (4-Methoxyphenyl) methanol) is a naturally derived volatile aromatic compound. 4-Methoxybenzyl alcohol upregulates the phosphorylation level of PI3K/Akt pathway proteins, downregulates the expression of pro-inflammatory factors, increases the content of tight junction proteins occludin and claudin-5, and alleviates structural damage to the blood-brain barrier. 4-Methoxybenzyl alcohol improves the decrease in viability and NO level of cerebral microvascular endothelial cells induced by oxygen-glucose deprivation/reperfusion, and reduces the release of lactate dehydrogenase. 4-Methoxybenzyl alcohol serves as a substrate in the two-phase persulfate-mediated electro-oxidation system, where it is directionally oxidized to p-anisaldehyde. 4-Methoxybenzyl alcohol acts as a substrate for wild-type fungal aryl alcohol oxidase. 4-Methoxybenzyl alcohol can be used in studies related to ischemic stroke, as well as in research across various fields such as chemical synthesis, including the synthesis of fragrances and flavorings.
Drug Intermediate   Interleukin Related   TNF Receptor   Claudin   Akt   NO Synthase  
/
HY-P99877 Efavaleukin alfa
Efavaleukin alfa (AMG592) is a IL-2 mutein fragment crystallizable fusion protein. Efavaleukin alfa drives the selective expansion of regulatory T cells. Efavaleukin alfa is applicable to research related to systemic lupus erythematosus.
Biochemical Assay Reagents  
Systemic Lupus Erythematosus  
/
HY-P991127 Claseprubart
Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis.

Species: Human

Complement System  
Myasthenia gravis  
/
HY-P99450 Avdoralimab
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research.

Species: Human

Complement System  
Cancer   Inflammation or Immune System Disease  
/
HY-NP0194A C1q Protein (mouse)
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease.
Complement System  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-134222A N-Acetylserine
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification.
Endogenous Metabolite   Complement System  
/
HY-145727 Volanesorsen
Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
Apolipoprotein  
Metabolic or Endocrine Disease  
/
HY-W011824 2′-O-Methyluridine
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

Source: Archaea, Bacteria, and Eukaryota

Endogenous Metabolite   Apolipoprotein  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-145727A Volanesorsen sodium
Volanesorsen (ISIS 304801) sodium is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen sodium is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
Apolipoprotein  
Metabolic or Endocrine Disease  
/
HY-152857 Muvalaplin
Muvalaplin (LY3473329) is an orally active small molecule apolipoprotein a (apolipoprotein a) inhibitor that binds to the KIV8 domain (Kd = 22 nM) and kringle IV domains 7 and 8, blocks the non-covalent interaction between apo (a) and apoB-100, and prevents Lp (a) assembly, thereby lowering circulating Lp (a) levels. Muvalaplin can be used in research on atherosclerotic cardiovascular disease.
Apolipoprotein  
Atherosclerosis  
/
HY-P990125 Anti-Mouse CSF1R/CD115 Antibody (AFS98)
Anti-Mouse (CSF1R/CD115) Antibody (AFS98) is an anti-mouse CSF1R IgG2a antibody inhibitor derived from rats. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) inhibits M-CSF-dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) can be used for the researches of inflammation, metabolic disease, cardiovascular disease and neurological disease, such as such as stroke, diabetes and arthritis.

Species: Mouse

c-Fms  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Arthritis   Atherosclerosis   Type 2 Diabetes  
/
HY-NP004 Cobra Venom Factor
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
Complement System  
Inflammation or Immune System Disease   Pulmonary Disease  
/
HY-P990706 Povetacicept
Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-110281 Dehydroascorbic acid
Dehydroascorbic acid is an oxidized form of vitamin C that can cross the blood-brain barrier (BBB). Dehydroascorbic acid clears cytotoxic reactive oxygen species (ROS) produced after ischemic stroke by converting to ascorbic acid (AA), thereby reducing neuronal and glial cell damage and stabilizing cerebral microvascular NO signaling to maintain perfusion in the ischemic area. Dehydroascorbic acid can be used in research on ischemic stroke.
Endogenous Metabolite  
Ischemic Stroke  
/
HY-P7517A Annexin A5/ANXA5 Protein, Human
Annexin A5 Protein, Human is a 35 kDa multifunctional protein which belongs to the annexin family. Annexin A5 induces in vitro fusion and aggregation of vesicles in a Ca2+- and acidic-pH-dependent manner.Annexin A5 is accepted as an early marker of apoptosis. Annexin A5 has anti-thrombotic and anti-microbial properties.

Species: Human; Source: E. coli

/
HY-P7534A Apolipoprotein H/APOH Protein, Mouse (HEK293, His)
Apolipoprotein H/APOH protein binds to heparin, phospholipids, and dextran sulfate, preventing activation of the blood coagulation cascade by interacting with phospholipids on damaged cell surfaces. Apolipoprotein H/APOH Protein, Mouse (HEK293, His) is the recombinant mouse-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

/
HY-P74371 C7/Complement component C7 Protein, Human (HEK293, His, solution)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, His, solution) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 7

/
HY-P702573 Annexin A5/ANXA5 Protein, Mouse (His, Myc)
The annexin A5 (ANXA5) protein acts as an anticoagulant, indirectly inhibiting the thromboplastin-specific complex, which is critical in the coagulation cascade. As a monomer, ANXA5 plays a key role in regulating the coagulation pathway, affecting the delicate balance between pro- and anti-coagulant factors. Annexin A5/ANXA5 Protein, Mouse (His, Myc) is the recombinant mouse-derived Annexin A5/ANXA5 protein, expressed by E. coli , with N-10*His, C-Myc labeled tag.

Species: Mouse; Source: E. coli

/
HY-P74373 C6/Complement component C6 Protein, Human (HEK293, His)
C6/Complement component C6 Protein is a part of the lytic membrane attack complex formed during complement activation, which has an indispensable role in innate and acquired immune responses by forming pores in the plasma membrane of target cells, as well as cancer immune surveillance. It is a component of the complement cascade which can be incorporated into the cell membrane and cause cell lysis. People with C6 deficiency are prone to bacterial infection. C6/Complement component C6 Protein, Human (HEK293, His) is the recombinant human-derived C6/Complement component C6 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 6

/
HY-P74374 C2/Complement C2 Protein, Mouse (HEK293, His)
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Complement System Complement Component 2

/
HY-P74371A C7/Complement component C7 Protein, Human (HEK293, C-10*His)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, C-10*His) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293, with C-10*His labeled tag.

Species: Human; Source: HEK293

/
HY-P74372 C7/Complement component C7 Protein, Human (HEK293, Fc)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, Fc) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 7

/
HY-P73630A SSB Protein, Human
The SSB protein critically binds to the 3' poly(U) terminus of RNA polymerase III transcripts, preventing exonuclease digestion and aiding in correct folding. In coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES) and enhances IRES-mediated translation. SSB Protein, Human is the recombinant human-derived SSB protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P7517 Annexin A5/ANXA5 Protein, Human (solution)
Annexin A5 Protein, Human is a 35 kDa multifunctional protein which belongs to the annexin family. Annexin A5 induces in vitro fusion and aggregation of vesicles in a Ca2+- and acidic-pH-dependent manner.Annexin A5 is accepted as an early marker of apoptosis. Annexin A5 has anti-thrombotic and anti-microbial properties.

Species: Human; Source: E. coli

/
HY-P700015AF Animal-Free Annexin A5/ANXA5 Protein, Human (His)
Annexin A5 (ANXA5) protein acts as an anticoagulant, indirectly inhibiting the thromboplastin-specific complex in the coagulation cascade. ANXA5 exists as a monomer and its role is not limited to coagulation regulation, but also has binding interactions involving ATRX and EIF5B, suggesting its involvement in a variety of cells. Animal-Free Annexin A5/ANXA5 Protein, Human (His) is the recombinant human-derived animal-FreeAnnexin A5/ANXA5 protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

Species: Human; Source: E. coli

Animal-free Recombinant Proteins

/
HY-P72079 Annexin A4/ANXA4 Protein, Mouse (His-Myc)
The Annexin A4/ANXA4 protein is a calcium/phospholipid-binding protein that plays a key role in membrane dynamics by promoting membrane fusion and exocytosis. This protein exhibits specific affinity for calcium ions and phospholipids, allowing it to participate in cellular processes involving membrane interactions. Annexin A4/ANXA4 Protein, Mouse (His-Myc) is the recombinant mouse-derived Annexin A4/ANXA4 protein, expressed by E. coli , with N-10*His, C-Myc labeled tag.

Species: Mouse; Source: E. coli

/
HY-P74410 Apolipoprotein H/APOH Protein, Rat (HEK293, His)
Apolipoprotein H/APOH proteins have multiple functions and can bind to negatively charged substances such as heparin and phospholipids. Its diverse interactions highlight the adaptability that is critical for preventing activation of the intrinsic coagulation cascade by binding to phospholipids on the surface of damaged cells. Apolipoprotein H/APOH Protein, Rat (HEK293, His) is the recombinant rat-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

/
HY-P705312 Complement C9 Protein, Human (His, Myc)

Species: Human; Source: E. coli

Complement System Complement Component 9

/
HY-P73629 SSB Protein, Human (sf9, His)
The SSB protein critically binds to the 3' poly(U) terminus of RNA polymerase III transcripts, preventing exonuclease digestion and aiding in correct folding. In coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES) and enhances IRES-mediated translation. SSB Protein, Human (sf9, His) is the recombinant human-derived SSB protein, expressed by Sf9 insect cells , with N-His labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P74376 C2/Complement C2 Protein, Human (HEK293, Fc)
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, Fc) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 2

/
HY-P73630 SSB Protein, Human (His)
The SSB protein critically binds to the 3' poly(U) terminus of RNA polymerase III transcripts, preventing exonuclease digestion and aiding in correct folding. In coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES) and enhances IRES-mediated translation. SSB Protein, Human (His) is the recombinant human-derived SSB protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

/
HY-P700660 Apolipoprotein H/APOH Protein, Cynomolgus (HEK293, His)
Apolipoprotein H/APOH proteins have multiple functions and can bind to negatively charged substances such as heparin and phospholipids. Its diverse interactions highlight the adaptability that is critical for preventing activation of the intrinsic coagulation cascade by binding to phospholipids on the surface of damaged cells. Apolipoprotein H/APOH Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

/
HY-P700697 C2/Complement C2 Protein, Cynomolgus (HEK293, His)
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

Complement System Complement Component 2

/
HY-P702610 Annexin A4 Protein, Human (His-SUMO, Myc)
Annexin A4 Protein, Human (His-SUMO, Myc) is the recombinant human-derived Annexin A4, expressed by E. coli, with C-Myc, N-SUMO, N-10*His labeled tag.

Species: Human; Source: E. coli

/
HY-P705191 C2/Complement C2 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi)

Species: Cynomolgus; Source: HEK293

Complement System Biotinylated Proteins Complement Component 2

/
HY-P705208 Annexin A5/ANXA5 Protein, Human (Biotinylated, His-Avi)
Annexin A5 Protein, Human is a 35 kDa multifunctional protein which belongs to the annexin family. Annexin A5 induces in vitro fusion and aggregation of vesicles in a Ca2+- and acidic-pH-dependent manner. Annexin A5 is accepted as an early marker of apoptosis. Annexin A5 has anti-thrombotic and anti-microbial properties. Annexin A5/ANXA5 Protein, Human (Biotinylated, His-Avi) is a recombinant biotinylated Annexin A5 protein expressed by E.coli and tagged with His-Avi.

Species: Human; Source: E. coli

Biotinylated Proteins

/
HY-P80015 Annexin-2/ANXA2 Antibody (YA619)
Annexin-2/ANXA2 Antibody (YA619) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Annexin-2/ANXA2.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82966 Annexin-2/ANXA2 Antibody (YA2711)
Annexin-2/ANXA2 Antibody (YA2711) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Annexin-2/ANXA2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80577 C3 Antibody (YA575)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80202 Ku70 Antibody (YA715)
Ku70 Antibody (YA715) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Ku70.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

/
HY-P82716 Protein C Antibody (YA2461)
Protein C Antibody (YA2461) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Protein C.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85879 Annexin-2/ANXA2 Antibody (YA5571)
Annexin-2/ANXA2 Antibody (YA5571) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Annexin-2/ANXA2.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P87668 ANXA5 Antibody (YA7353)
ANXA5 Antibody (YA7353) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to ANXA5.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810367 Complement factor B Antibody
Complement factor B Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P810847 Annexin A3 Antibody
Annexin A3 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Annexin A3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P80577A C3 Antibody (YA575)(PBS only)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810481 SSB Antibody (YA9778)
SSB Antibody (YA9778) is a Mouse-derived and non-conjugated IgG1 Monoclonal antibody, targeting to SSB.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P81468 C1QA Antibody (YA1213)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81468A C1QA Antibody (YA1213)(PBS only)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82966A Annexin-2/ANXA2 Antibody (YA2711)(PBS only)
Annexin-2/ANXA2 Antibody (YA2711) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Annexin-2/ANXA2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83239 Complement factor B Antibody (YA2984)
Complement factor B Antibody (YA2984) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85597 Ku70 Antibody (YA5289)
Ku70 Antibody (YA5289) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Ku70.

Host: Mouse; Reactivity: Human, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P86517 Adiponectin Antibody (YA6209)
Adiponectin Antibody (YA6209) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Adiponectin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86840 Complement C5 Antibody (YA6533)
Complement C5 Antibody (YA6533) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement C5.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87384 C7 Antibody (YA7067)
C7 Antibody (YA7067) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C7.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/

Keywords

antiphospholipid antibodies | antiphospholipid syndrome | cardiovascular thrombosis | lupus anticoagulant | β2-glycoprotein I | thromboinflammation | stroke | complement